MedTrace Logo

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

NCT07001865 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 17040

Last updated 2025-06-03

No results posted yet for this study

Summary

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Metabolically Healthy Obesity
  • Hyperuricemia

Sponsors & Collaborators

  • Ningbo No. 1 Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07001865 on ClinicalTrials.gov